RxDoctor Payments Data

Julie Price, MD

Internal Medicine · Troy, MINPI 1619944352

Payments from drug & device makers

$3,246in general payments, 2019–2025

Across 128 payments — averaging $25.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$852
  • Novo Nordisk$421
  • AstraZeneca$280
  • Pfizer$270
  • AbbVie$244
  • Merck$207
  • plus $973 from 14 others

What the payments were for

  • Food & beverage$3,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,246 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$287,327
Medicare patients
351
Services billed
7,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$53,368
EliquisApixaban62$48,125
MounjaroTirzepatide24$30,864
JardianceEmpagliflozin27$30,235
TrulicityDulaglutide16$23,921
XareltoRivaroxaban15$11,444
ShingrixVaricella-Zoster Ge/As01b/Pf39$8,689
Rosuvastatin Calcium316$5,300
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$4,856
Atorvastatin Calcium371$4,453
Levothyroxine Sodium335$4,000
Boostrix TdapDiphth,pertuss(Acell),tet Vac54$3,943
Losartan Potassium249$3,334
Ipratropium Bromide76$3,253
SynthroidLevothyroxine Sodium39$3,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$197$54,78540 claims
Novo NordiskOzempic$421$53,36856 claims
PfizerEliquis$270$48,12562 claims
Boehringer IngelheimJardiance$152$30,23527 claims
Johnson & JohnsonXarelto$72$11,44415 claims
GSKShingrix$43$8,68939 claims
AbbVieSynthroid$244$3,08939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →